Glytrix is focused on the cost-efficient development of its technology through a virtual company structure under the leadership of experienced scientists and biotech business executives, and through a partnership with Benu BioPharma. Glytrix plans to develop each indication through clinical proof of concept and then transfer the technology to a corporate partner to complete development and commercialization.
Dr. Goldberg has more than 20 years of experience in the pharmaceutical and biotechnology industries, ranging from drug discovery at a Fortune 25 company to chief executive officer of "virtual" biotechnology companies. Dr. Goldberg has served as President, CEO and Founder of Transport Pharmaceuticals, Inc., and Talaria Therapeutics, which developed the Large Unilamellar Vesicle (LUV) technology. Talaria Therapeutics was acquired by Esperion Therapeutics (NASDAQ:ESPR) less than two years after its formation.
Dr. Goldberg was also Vice President of Product development and Regulatory Affairs at GelTex Pharmaceuticals (NASDAQ:GELX), where he was responsible for all biological and clinical development activities at the company, leading to the approval of RenaGel® and WelChol®. He was also Science Coordinator for the Atherosclerosis Research Program at Pfizer Central Research.
Dr. Friden has twenty years experience in the biopharmaceutical industry taking products from concept through proof of concept clinical studies. This includes twelve years working in virtual/semi-virtual companies. Most recently, Dr. Friden was Vice President of Research & Development and Clinical Operations at Transport Pharmaceuticals, which included responsibility for development of all new products, two of which went from concept into clinical testing.
Dr. Friden was formerly vice president of biology at Scion Pharmaceuticals, a start-up biotechnology company focused on small molecule drug discovery of ion channel modulators. Prior to Scion, Dr. Friden was vice president of Research & Development at Periodontix (acquired by Demegen in 2001) where he managed a team focused on the development of multiple novel peptide-based treatments for chronic infections. Dr. Friden is an inventor on nineteen issued U.S. patents and has published more than fifty peer-reviewed papers and book chapters.
Dr. Morrel has been working in the biotechnology industry for over twenty years and in clinical research for the last thirteen. Dr. Morrel was previously Vice President of Clinical Research at Transport Pharmaceuticals, Inc. where he was responsible for the design and writing of all clinical Phase 1-3 Protocols, participated in the management and execution of those trials and contributed the clinical sections for all regulatory submissions.
Prior to joining Transport, Dr. Morrel was associate director of clinical operations at Transkaryotic Therapeutics, Inc. (TKTI) where he was responsible for the execution and management of TKTI's gene therapy Clinical Trial. Dr. Morrel began his work in clinical Research at Ascent Pediatrics, Inc., a virtual company focused on reformulating drugs for the pediatric market, where he was assistant director of medical affairs. At Ascent he managed multiple phase 1-3 trials, including selecting, negotiating and managing the contracts of the CROs.
Dr. Panitch is the Associate Head of Biomedical Engineering and Professor at Purdue University. Her research in biomimetic materials, peptide therapeutics, and regenerative medicine has led to numerous publications and patents, and the launch of three independent companies.
She was also appointed Faculty Entrepreneur in Residence and is sharing her experiences to build a network and guide entrepreneurial endeavors of faculty, staff, and students at Purdue.
Dr. Paderi is an inventor of Glytrix's peptidoglycan technology and has over eight years of biomaterials R&D with extensive experience with collagen and biomimetic materials.
He is an inventor on five patents and was a Purdue Realization in Entrepreneurship Postdoctoral fellow that led to the formation of Glytrix.
Dr. Stuart has more than eleven years of R&D experience in collagen based tissues and tissue engineered scaffolds. She is an inventor on three patents relating to Glytrix's peptidoglycan technology, and is an expert in collagen-glycosaminoglycan scaffolds for vascular tissue engineering.
She is also a Howard Hughes Medical Institute fellow bridging her research expertise with course curricula.
